Federica Pecci
机构：University of Parma, Dana-Farber Cancer Institute · ORCID：0009-0000-9289-2007
发表论文 676 篇 · 总被引 1675 次 · h-index 23
代表论文
- Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study (2026 · The Oncologist)
- Supplementary Figure 6 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)
- Supplementary Figure 3 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)
- Supplementary Table 3 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)
- Supplementary Figure 13 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)
- Supplementary Table 20 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)